» Authors » Walter E Aulitzky

Walter E Aulitzky

Explore the profile of Walter E Aulitzky including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 35
Citations 869
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Beigl T, Paul A, Fellmeth T, Nguyen D, Barber L, Weller S, et al.
EMBO Rep . 2024 Jul; 25(9):3896-3924. PMID: 39048751
The Bcl-2 family controls apoptosis by direct interactions of pro- and anti-apoptotic proteins. The principle mechanism is binding of the BH3 domain of pro-apoptotic proteins to the hydrophobic groove of...
2.
Bopple K, Oren Y, Henry W, Dong M, Weller S, Thiel J, et al.
Cell Death Dis . 2024 Apr; 15(4):290. PMID: 38658567
High-grade serous ovarian cancer (HGSOC) represents the most common and lethal subtype of ovarian cancer. Despite initial response to platinum-based standard therapy, patients commonly suffer from relapse that likely originates...
3.
Dong M, Bopple K, Thiel J, Winkler B, Liang C, Schueler J, et al.
Cells . 2023 Mar; 12(5). PMID: 36899943
Precision-cut tumor slices (PCTS) maintain tissue heterogeneity concerning different cell types and preserve the tumor microenvironment (TME). Typically, PCTS are cultured statically on a filter support at an air-liquid interface,...
4.
Aylon Y, Furth N, Mallel G, Friedlander G, Nataraj N, Dong M, et al.
Nat Commun . 2023 Jan; 14(1):133. PMID: 36627302
No abstract available.
5.
Aylon Y, Furth N, Mallel G, Friedlander G, Nataraj N, Dong M, et al.
Nat Commun . 2022 Nov; 13(1):7199. PMID: 36443319
Breast cancer, the most frequent cancer in women, is generally classified into several distinct histological and molecular subtypes. However, single-cell technologies have revealed remarkable cellular and functional heterogeneity across subtypes...
6.
Weller S, Toenniessen A, Schaefer B, Beigl T, Muenchow A, Bopple K, et al.
Cell Death Discov . 2022 Apr; 8(1):215. PMID: 35443750
Enhanced expression of anti-apoptotic B-cell lymphoma 2 (BCL-2) protein is frequent in cancer. Targeting of BCL-2 with the specific inhibitor ABT-199 (Venetoclax) has significant clinical activity in malignant diseases such...
7.
Horak P, Heining C, Kreutzfeldt S, Hutter B, Mock A, Hullein J, et al.
Cancer Discov . 2021 Jun; 11(11):2780-2795. PMID: 34112699
The clinical relevance of comprehensive molecular analysis in rare cancers is not established. We analyzed the molecular profiles and clinical outcomes of 1,310 patients (rare cancers, 75.5%) enrolled in a...
8.
Kayser S, Schlenk R, Lebon D, Carre M, Gotze K, Stolzel F, et al.
Haematologica . 2021 May; 106(12):3100-3106. PMID: 34047178
The aim of this study was to characterize a large series of 154 patients with acute promyelocytic leukemia (median age, 53 years; range, 18-90 years) and evaluate real-life outcome after...
9.
Muenchow A, Weller S, Hinterleitner C, Malenke E, Bugl S, Wirths S, et al.
Cell Death Dis . 2020 Aug; 11(8):701. PMID: 32839432
Soft tissue sarcomas (STS) are a heterogeneous group of malignancies predominantly affecting children and young adults. Despite improvements in multimodal therapies, 5-year survival rates are only 50% and new treatment...
10.
Kleih M, Bopple K, Dong M, Gaissler A, Heine S, Olayioye M, et al.
Cell Death Dis . 2019 Nov; 10(11):851. PMID: 31699970
Patients with high-grade serous ovarian cancer (HGSC) frequently receive platinum-based chemotherapeutics, such as cisplatin. Cisplatin binds to DNA and induces DNA-damage culminating in mitochondria-mediated apoptosis. Interestingly, mitochondrial DNA is critically...